SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Sun Pharma receives USFDA nod for anti-anxiety drug

21 Jun 2010 Evaluate

Sun Pharmaceutical Industries has received the US Food and Drug Administration's nod to market a generic version of alprazolam, an anti-anxiety drug, in the US market. The company has received the USFDA's nod for marketing generic alprazolam tablets in four strengths, 0.25 mg, 0.55 mg, 1 mg and 2 mg, in the US market.

Generic alprazolam tablets are equivalent to Pfizer's patented Xanax tablets. Alprazolam has annual sales of USD 145 million in the United States. On Thursday, the company had received the US health regulator's nod for marketing a generic version of the Keppra injection, used for treating epilepsy, in the American market.

crackcrack

Sun Pharma Inds. Share Price

1675.20 -17.95 (-1.06%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×